Previous 10 |
ImmunityBio ([[IBRX]] +7.3%) posts positive preclinical data highlighting efficacy of the company's PD-L1 t-haNK natural killer cell-based therapy in combination with T cell-based immunotherapy against heterogeneous tumors.The study supports ImmunityBio’s hypothesis of combining N...
Checkpoint therapy alone is unlikely to lead to durable tumor control or a cure in patients with solid tumors that harbor DNA mutations that make them invisible to T cells This study supports ImmunityBio’s hypothesis of combining NK cells with T cell activation in Phase 2/3...
Interim data on 12 participants from ImmunityBio's (IBRX) phase 1 trial of its T cell-based COVID-19 vaccine showed none experienced any serious adverse events.The vaccine was given in sublingual and oral formulations.The company is also examining the vaccine in a subcutaneous formulation.Ful...
Safety assessments completed for first 12 participants and no serious adverse events (SAEs) reported; trials expected to be fully enrolled in Q2 First COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple routes—subcutaneous, sublin...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...